Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Over the nine years from 2004 Wiedermann et al. had developed a B cell peptide cancer immunotherapy that could induce an antibody response targeting HER-2 overexpressing tumours.

In 2019 the company then licensed the CF33 oncolytic virus platform, invented by renowned oncologist Professor Yuman Fong of City of Hope Cancer Center in California, USA.

Researchers showed significant activity with mice being cured of their cancer with the CF33-CD19 and CAR T-cell combination, as well as prolonged protective anti-tumour immunity.

Developed by Professor Pravin Kaumaya at the Ohio State University in Columbus OH, the immunotherapy is constructed from a single B cell epitope derived from the extracellular domain of PD-1.